Recursion Year-End 2024 Recap

💨 In 2024, we moved fast to scale on all fronts.
✍ Luckily, we kept track of all the memorable moments along the way.
🔹 In January, we unveiled LOWE at JPM - a new LLM tool that lets researchers query our biological and chemical datasets to find new targets and design new molecules.
🔹 In March, we announced we were opening a new office in London - tapping into Europe’s leading AI hub.
🔹 In May, we finished building BioHive-2 with NVIDIA - the fastest supercomputer in the pharma industry.
🔹 In June, we welcomed Najat Khan, PhD from J&J as our new Chief R&D and Chief Commercial Officer.
🔹 And at Download Day NVIDIA CEO Jensen Huang joined cofounder and CEO Chris Gibson to discuss how we’re poised to lead the digital biology revolution.
🔹 In August, we completed the world’s first neuroscience phenomap or “Neuromap” with our pharma partners.
🔹 In September, we released promising Phase 2 data for REC-994 - our lead drug and the first oral treatment for cerebral cavernous malformation.
🔹 In October, we announced the expansion of our partnership with Google Cloud.
🔹 And the first patient was dosed in our Phase 2 clinical trial for REC-3964 for the treatment of recurrent C. diff.
🔹 In November, we released OpenPhenom - a publicly available foundation model built on microscopy data that sets a new standard - outperforming CellProfiler.
🔹 And we officially combined with Exscientia to become the industry’s leading hashtag#TechBio powerhouse across pipeline, partnerships, and platform.
🔹 In December, the first patient was dosed in our Phase 1 / 2 trial of REC-1245, an RBM39 degrader for solid tumors and lymphoma.
🔹 And we shared interim Phase 1 Data for REC-617, a potential best in class CDK7 inhibitor for advanced solid tumors - with encouraging patient response and favorable tolerability.
🎉 It was an incredible year - and we’re just getting started!
❄️ A very happy holiday and happy new year to our incredible team of Recursionauts, friends, partners, and investors. See you in 2025!